Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.

Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M, Superti-Furga G, Jäger U, Bock C.

Nat Chem Biol. 2019 Mar;15(3):232-240. doi: 10.1038/s41589-018-0205-2. Epub 2019 Jan 28.

PMID:
30692684
2.

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.

Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B.

Blood. 2018 Dec 17. pii: blood-2018-06-856930. doi: 10.1182/blood-2018-06-856930. [Epub ahead of print]

PMID:
30559259
3.

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators.

N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.

PMID:
30501490
4.

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, Schuh A, Stilgenbauer S.

Haematologica. 2018 Nov 15. pii: haematol.2018.187583. doi: 10.3324/haematol.2018.187583. [Epub ahead of print]

5.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2018 Aug 21. doi: 10.1038/s41375-018-0239-1. [Epub ahead of print]

PMID:
30131584
6.

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O.

Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018 Aug 3. Review.

7.

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13. Review.

8.

Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells.

Vašíček J, Shehata M, Schnabl S, Hilgarth M, Hubmann R, Jäger U, Bauer M, Chrenek P.

Biotechnol Prog. 2018 Sep;34(5):1278-1289. doi: 10.1002/btpr.2659. Epub 2018 Aug 6.

PMID:
29882300
9.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.

Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.

10.

Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.

Schoergenhofer C, Schwameis M, Firbas C, Bartko J, Derhaschnig U, Mader RM, Plaßmann RS, Jilma-Stohlawetz P, Desai K, Misra P, Jäger U, Jilma B.

Sci Rep. 2018 Jan 9;8(1):124. doi: 10.1038/s41598-017-17934-6.

11.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP.

EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. Review.

12.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G.

Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.

13.

Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Thallinger C, Füreder T, Preusser M, Heller G, Müllauer L, Höller C, Prosch H, Frank N, Swierzewski R, Berger W, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91. doi: 10.1007/s00508-017-1285-9. Epub 2017 Nov 2. Review.

14.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P.

Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. eCollection 2017 Sep 15.

15.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB.

Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.

16.

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S.

Leukemia. 2017 Dec;31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14. No abstract available.

PMID:
28804126
17.

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.

Hansson L, Asklid A, Diels J, Eketorp-Sylvan S, Repits J, Søltoft F, Jäger U, Österborg A.

Ann Hematol. 2017 Oct;96(10):1681-1691. doi: 10.1007/s00277-017-3061-3. Epub 2017 Jul 31.

18.

Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.

Skrabs C, Pickl WF, Perkmann T, Jäger U, Gessl A.

J Clin Pharm Ther. 2018 Feb;43(1):145-149. doi: 10.1111/jcpt.12602. Epub 2017 Jul 28.

PMID:
28753229
19.

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G.

Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12. No abstract available.

PMID:
28745332
20.

Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.

Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, Shehata M.

Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. eCollection 2017.

21.

Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma.

Bauer WM, Aichelburg MC, Griss J, Skrabs C, Simonitsch-Klupp I, Schiefer AI, Kittler H, Jäger U, Zeyda M, Knobler R, Stingl G.

Br J Dermatol. 2018 Jan;178(1):215-221. doi: 10.1111/bjd.15841. Epub 2017 Dec 29.

PMID:
28733977
22.

Global survey of the immunomodulatory potential of common drugs.

Vladimer GI, Snijder B, Krall N, Bigenzahn JW, Huber KVM, Lardeau CH, Sanjiv K, Ringler A, Berglund UW, Sabler M, de la Fuente OL, Knöbl P, Kubicek S, Helleday T, Jäger U, Superti-Furga G.

Nat Chem Biol. 2017 Jun;13(6):681-690. doi: 10.1038/nchembio.2360. Epub 2017 Apr 24.

23.

RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.

Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki ÖY, Platzer R, Pfajfer L, Bilic I, Ban SA, Willmann KL, Mukherjee M, Supper V, Hsu HT, Banerjee PP, Sinha P, McClanahan F, Zlabinger GJ, Pickl WF, Gribben JG, Stockinger H, Bennett KL, Huppa JB, Dupré L, Sanal Ö, Jäger U, Sixt M, Tezcan I, Orange JS, Boztug K.

Nat Immunol. 2016 Dec;17(12):1352-1360. doi: 10.1038/ni.3575. Epub 2016 Oct 24.

PMID:
27776107
24.

Combined integrated protocol/basket trial design for a first-in-human trial.

Derhaschnig U, Gilbert J, Jäger U, Böhmig G, Stingl G, Jilma B.

Orphanet J Rare Dis. 2016 Oct 4;11(1):134.

25.

Costs of haematological disease high and rising.

Green T, Bron D, Chomienne C, de Wit TD, de Haas F, Engert A, Hagenbeek A, Jäger U, MacIntyre E, Muckenthaler MU, Smand C, Sonneveld P.

Lancet Haematol. 2016 Aug;3(8):e353-4. doi: 10.1016/S2352-3026(16)30074-6. Epub 2016 Jul 22. No abstract available.

PMID:
27476782
26.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A.

Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16.

PMID:
27374465
27.

Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.

Freund P, Porpaczy EA, Le T, Gruber M, Pausz C, Staber P, Jäger U, Vanura K.

PLoS One. 2016 Jun 1;11(6):e0156693. doi: 10.1371/journal.pone.0156693. eCollection 2016.

28.

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.

Rabitsch W, Bojic M, Wohlfarth P, Leiner M, Schörgenhofer C, Kalhs P, Schulenburg A, Sillaber C, Mitterbauer M, Sperr WR, Jäger U, Skrabs K, Greinix H, Hermann A, Lamm W.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1307-14. doi: 10.1007/s00432-016-2134-3. Epub 2016 Feb 26.

29.

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.

Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA.

Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9. Epub 2016 Feb 5.

30.

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine.

Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, Smolen JS, Valenta R, Lassmann H, Kovar H, Jäger U, Kornek G, Müller M, Sörgel F.

J Innate Immun. 2016;8(2):111-20. doi: 10.1159/000443526. Epub 2016 Feb 5.

31.

Blood disorders stepping into the limelight.

Jäger U, Chomienne C, Cools J, Smand C.

Haematologica. 2016 Feb;101(2):101-3. doi: 10.3324/haematol.2016.142018. Epub 2016 Jan 27. No abstract available.

32.

Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma.

Wohlfarth P, Carlström A, Staudinger T, Clauss S, Hermann A, Rabitsch W, Bojic A, Skrabs C, Porpaczy E, Schiefer AI, Valent P, Knöbl P, Agis H, Hauswirth A, Jäger U, Kundi M, Sperr WR, Schellongowski P; Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin (ÖGIAIN).

Leuk Lymphoma. 2016 Aug;57(8):1831-8. doi: 10.3109/10428194.2015.1106537. Epub 2016 Jan 13.

PMID:
26758791
33.

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.

Schiefer AI, Kornauth C, Simonitsch-Klupp I, Skrabs C, Masel EK, Streubel B, Vanura K, Walter K, Migschitz B, Stoiber D, Sexl V, Raderer M, Chott A, da Silva MG, Cabecadas J, Müllauer L, Jäger U, Porpaczy E.

Medicine (Baltimore). 2015 Dec;94(52):e2388. doi: 10.1097/MD.0000000000002388.

34.

Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia.

Kulpa J, Skrabs C, Simanek R, Valent P, Panzer S, Lechner K, Sillaber C, Jäger U.

Wien Klin Wochenschr. 2016 Apr;128(7-8):234-7. doi: 10.1007/s00508-015-0863-y. Epub 2015 Sep 24.

PMID:
26404740
35.

Recurrent alterations of TNFAIP3 (A20) in T-cell large granular lymphocytic leukemia.

Johansson P, Bergmann A, Rahmann S, Wohlers I, Scholtysik R, Przekopowitz M, Seifert M, Tschurtschenthaler G, Webersinke G, Jäger U, Siebert R, Klein-Hitpass L, Dührsen U, Dürig J, Küppers R.

Int J Cancer. 2016 Jan 1;138(1):121-4. doi: 10.1002/ijc.29697. Epub 2015 Jul 30.

36.

Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin.

Schneeweiss M, Porpaczy E, Koch M, Jonak C, Schiefer AI, Simonitsch-Klupp I, Sillaber C, Mayerhöfer M, Jäger U.

Leuk Lymphoma. 2016;57(1):206-8. doi: 10.3109/10428194.2015.1044748. Epub 2015 Jun 19. Review. No abstract available.

PMID:
25907615
37.

SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.

Brunhofer-Bolzer G, Le T, Dyckmanns N, Knaus HA, Pausz C, Freund P, Jäger U, Erker T, Vanura K.

J Med Chem. 2015 Feb 12;58(3):1244-53. doi: 10.1021/jm501848m. Epub 2015 Jan 20.

PMID:
25562417
38.

Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis.

Geissler K, Jäger E, Öhler L, Gisslinger H, Jäger U, Lechner K.

Eur J Haematol. 2015 Sep;95(3):239-43. doi: 10.1111/ejh.12486. Epub 2015 Jan 7.

PMID:
25404526
39.

Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.

Gebhart J, Lechner K, Skrabs C, Sliwa T, Müldür E, Ludwig H, Nösslinger T, Vanura K, Stamatopoulos K, Simonitsch-Klupp I, Chott A, Quehenberger P, Mitterbauer-Hohendanner G, Pabinger I, Jäger U, Geissler K.

Thromb Res. 2014 Nov;134(5):980-4. doi: 10.1016/j.thromres.2014.08.021. Epub 2014 Aug 29.

PMID:
25201005
40.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d'Amore F, Tilly H, Zinzani PL.

Cancer Treat Rev. 2014 Oct;40(9):1080-8. doi: 10.1016/j.ctrv.2014.08.001. Epub 2014 Aug 24. Review.

41.

A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.

Fink SE, Gandhi MK, Nourse JP, Keane C, Jones K, Crooks P, Jöhrens K, Korfel A, Schmidt H, Neumann S, Tiede A, Jäger U, Dührsen U, Neuhaus R, Dreyling M, Borchert K, Südhoff T, Riess H, Anagnostopoulos I, Trappe RU.

Am J Transplant. 2014 Nov;14(11):2577-87. doi: 10.1111/ajt.12858. Epub 2014 Aug 4.

42.

Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings.

Arthold C, Skrabs C, Mitterbauer-Hohendanner G, Thalhammer R, Simonitsch-Klupp I, Panzer S, Valent P, Lechner K, Jäger U, Sillaber C.

Wien Klin Wochenschr. 2014 Jun;126(11-12):376-82. doi: 10.1007/s00508-014-0547-z. Epub 2014 May 20.

PMID:
24842748
43.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M.

Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.

44.

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.

Cerny-Reiterer S, Meyer RA, Herrmann H, Peter B, Gleixner KV, Stefanzl G, Hadzijusufovic E, Pickl WF, Sperr WR, Melo JV, Maeda H, Jäger U, Valent P.

Oncotarget. 2014 Mar 15;5(5):1198-211.

45.

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H.

Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20.

46.

Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia.

Pöchlauer S, Jäger E, Jäger U, Geissler K.

Ann Hematol. 2014 Oct;93(10):1775-6. doi: 10.1007/s00277-014-2012-5. Epub 2014 Jan 18. No abstract available.

PMID:
24441916
47.

Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS).

Riedl J, Kaider A, Reitter EM, Marosi C, Jäger U, Schwarzinger I, Zielinski C, Pabinger I, Ay C.

Thromb Haemost. 2014 Apr 1;111(4):670-8. doi: 10.1160/TH13-07-0603. Epub 2013 Dec 5.

PMID:
24306221
48.

High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis.

Hauer V, Jäger E, Sliwa T, Simanek R, Gisslinger H, Jäger U, Geissler K.

Leuk Res. 2014 Jan;38(1):116-20. doi: 10.1016/j.leukres.2013.10.003. Epub 2013 Oct 14.

PMID:
24262286
49.

Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma.

Kosulin K, Rauch M, Ambros PF, Pötschger U, Chott A, Jäger U, Drach J, Nader A, Lion T.

Eur J Cancer. 2014 Feb;50(3):622-7. doi: 10.1016/j.ejca.2013.10.013. Epub 2013 Nov 15.

PMID:
24246703
50.

Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia.

Vanura K, Rieder F, Kastner MT, Biebl J, Sandhofer M, Le T, Strassl R, Puchhammer-Stöckl E, Perkmann T, Steininger CF, Stamatopoulos K, Graninger W, Jäger U, Steininger C.

PLoS One. 2013 Oct 23;8(10):e78925. doi: 10.1371/journal.pone.0078925. eCollection 2013.

Supplemental Content

Support Center